Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2024
Principal Event: Announcement of data from an exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder.
Key Financial Metrics
This filing is a current report regarding clinical trial data and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary material event is the release of clinical data for the investigational drug SPN-820.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a webcast and conference call on October 17, 2024, to review the Phase 2a study data. Presentation slides are archived on the Company's website.
- Forward-Looking Statements: The report contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risks: Risks include ordinary business operations, general economic conditions, and market competition. Specific risk factors are referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Review the full press release (Exhibit 99.1) for specific efficacy and safety data from the SPN-820 Phase 2a study.
- Access the archived webcast and presentation slides on the Company's website for detailed management commentary.
- Consult the most recent Form 10-K or 10-Q for current financial health, cash position, and liquidity metrics, as this 8-K does not contain them.
- Monitor future filings for updates on the development timeline of SPN-820 following this data release.